Pharvaris (PHVS) announced that the European Commission has granted orphan designation to its investigational drug, deucrictibant, for the treatment of bradykinin-mediated angioedema. The U.S. FDA previously granted orphan drug designation to deucrictibant for the treatment of bradykinin-mediated angioedema in March 2022.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS: